Market Overview

Boston Scientific Commences Clinical Trial of Patients with INGEVITY Pacing Leads

Related BSX
St. Jude Medical Hits New Lifetime High - Analyst Blog
Wall Street Comfortable With Covidien Buy; Some See Move By Johnson & Johnson

The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads.  Pacing leads are insulated wires that connect an implantable pacemaker to the heart for treatment of bradycardia, a condition in which the heart beats too slowly, depriving the body of sufficient oxygen.  Pacemakers work in conjunction with leads to sense and stimulate (or pace) the heart, thus maintaining an appropriate heart rate for a given level of physical activity.

The INGEVITY pacing lead platform is designed to provide key enhancements in maneuverability, reliability, fixation and electrical performance compared to standard leads available today.  In addition, INGEVITY leads are specifically engineered to function in the magnetic resonance imaging (MRI) environment.  Many patients with pacemakers are restricted from undergoing MRI scans, as powerful magnets may interfere with pacemaker functionality.

Posted-In: News FDA

 

Most Popular

Related Articles (BSX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free